Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Must Reads by Date
Must reads for theWeek ending April 17, 2016
COBAS Diagnostic Gets Expanded Indication, Roche news release; 2016 March 21
Sofosbuvir Regimens in Liver Decompensation, J Viral Hepat; ePub 2016 Mar 17; Perumalswami, et al
Must reads for theWeek ending March 20, 2016
EMR Algorithms for Staging Fibrosis, J Clin Gastroenterol; ePub 2016 Mar 11; Anand, et al
HCV Burden to Medicare, Hepatology; ePub 2016 Feb 26; Rein, Borton, et al
Worldwide Prevalence of HIV Coinfection, Lancet Infect Dis; ePub 2016 Feb 24; Platt, et al
Serum Markers of Early Stage HCV, BMC Gastroenterol; 2016 Feb 29; Kataria, et al
Cytidine Deaminase After HCV Therapy, J Viral Hepat; ePub 2016 Mar 4; Cuéllar, et al
Must reads for theWeek ending March 6, 2016
HCV Prevalence in an Urban Emergency Department, Clin Infect Dis; ePub 2016 Feb 21; Lyons, et al
Association Between H. pylori and Chronic HCV, Gastroen Res Pract; ePub 2016 Jan 24; Wang, et al
Determining HCV Treatment Eligibility, PLoS One; ePub 2016 Feb 22; Rogal, et al
Activated Regulatory T-Cells as Risk Indicator, PLoS One; ePub 2016 Feb 22; Rogal, et al
Hepatocellular Carcinoma Recurrence in Patients With HCV, Oncology. 2016 ePub Feb 23. Kunimoto, Ikeda, et al
Must reads for theWeek ending February 14, 2016
FDA Approves Zepatier for HCV Genotypes 1 and 4, A once-daily, fixed dose combination
HCV in HIV+ Gay Men, Assessing prevalence with and without IV drug use
Treating HCV Without Interferon or Ribivarin, Studying patient-reported outcomes in older adults
Decompensation in Advanced Chronic Hepatitis C, Is incident hepatitis E infection a risk factor?
An All-oral Regimen for HCV Genotype 3 With Cirrhosis, Evaluating efficacy and safety of daclatasvir, sofosbuvir, and ribavirin
Must reads for theWeek ending January 31, 2016
Surgery for Patients With HCV, Studying risk of infectious complications
HCV Screening According to USPSTF Guidelines, Are community health centers conforming?
Dropout Rates and Morbidity of Ribavirin-inclusive HCV Therapies, Assessing the frequency of serious adverse events
Efficacy and Safety of Ledipasvir/Sofosbuvir, Evaluating its use with or without ribavirin
Overcoming Interferon Nonresponse in Chronic HCV, Can protease inhibitors help?